April 7th, 2017 – TORONTO, ON – (April 7, 2017) – Today, Canabo Medical Inc. (TSX-V:CMM) (OTCQB:CAMDF) (“Canabo” or the “Company”) released the results of a new, landmark observational study that connects doctor-supervised medical cannabis treatments to a sharp drop in benzodiazepine reliance among Canadian patients. Research conducted over the past year revealed that 40 per…